These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9621854)

  • 1. Effect of pramipexole in treatment of resistant restless legs syndrome.
    Lin SC; Kaplan J; Burger CD; Fredrickson PA
    Mayo Clin Proc; 1998 Jun; 73(6):497-500. PubMed ID: 9621854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
    Stiasny-Kolster K; Oertel WH
    Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
    Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
    Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
    Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
    Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
    Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
    Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting the efficacy of pramipexole in patients with restless legs syndrome.
    Rezvani M; Zamani B; Fereshtehnejad SM
    Acta Med Iran; 2013 Jul; 51(6):377-85. PubMed ID: 23852842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
    Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
    Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
    Montplaisir J; Denesle R; Petit D
    Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome.
    Shinno H; Oka Y; Otsuki M; Tsuchiya S; Mizuno S; Kawada S; Innami T; Sasaki A; Hineno T; Sakamoto T; Inami Y; Nakamura Y; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):522-6. PubMed ID: 20156514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of cortical excitability after dopaminergic treatment in restless legs syndrome.
    Scalise A; Pittaro-Cadore I; Janes F; Marinig R; Gigli GL
    Sleep Med; 2010 Jan; 11(1):75-81. PubMed ID: 19595629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of idiopathic and uremic restless legs syndrome].
    Trenkwalder C; Stiasny K; Oertel WH
    Nervenarzt; 1996 Apr; 67(4):265-76. PubMed ID: 8684504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with pramipexole in the treatment of restless legs syndrome.
    Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole in the management of restless legs syndrome: an extended study.
    Silber MH; Girish M; Izurieta R
    Sleep; 2003 Nov; 26(7):819-21. PubMed ID: 14655914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pramipexole in restless legs syndrome.
    Winkelman JW; Sethi KD; Kushida CA; Becker PM; Koester J; Cappola JJ; Reess J
    Neurology; 2006 Sep; 67(6):1034-9. PubMed ID: 16931507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restless legs syndrome improved by pramipexole: a double-blind randomized trial.
    Montplaisir J; Nicolas A; Denesle R; Gomez-Mancilla B
    Neurology; 1999 Mar; 52(5):938-43. PubMed ID: 10102409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
    Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
    Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.